Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection

Inclusion Criteria: Patient is ≥ 18 years of age; Voluntarily signed informed consent; Patient has a proven HIV-1 infection (with positive antibodies against HIV-1 and a detectable plasma HIV-1 RNA); Patient is HIV-1 treatment naïve; CD4+ T-cell count ≥ 350 x 10^6/L; Plasma HIV-1 RNA level at screening visit of at least 5.000 copies/ml, and not varying more than ± 0.5 log10 copies during the preceding 6 month period; Patient was participant in part 1 of the original Suc-HSA study (protocol no. 2003-002, version 2.4, dated 18 November 2003) and the administration of Suc-HSA occurred more than 8 weeks ago, OR patient was not participant in this study; Patient is one of the following: not heterosexually active, OR a heterosexually active female, agreeing to use an effective method of contraception with her partner (combined oral contraceptive pill; injectable contraceptive; intrauterine contraceptive device (IUCD); consistent use of condoms if using these; physiological or anatomical sterility in herself or her partner) from 14 days prior to the first administration of study medication until 4 months after the last, and willing to undergo urine pregnancy tests prior to the first and last administration, OR a heterosexually active male, agreeing to use an effective method of contraception with his partner from the day of the first administration until 4 months after the last administration. Exclusion Criteria: History of an AIDS defining event; Use of antiretroviral or immunomodulatory therapy; Any reason to start antiretroviral therapy at the time of enrolment or which is expected to occur during the course of the study at the time of enrolment; Presence of active, replicating hepatitis B and/or C virus co-infection; ASAT and/or ALAT > 3 times upper limit of normal (ULN) (AIDS Clinical Trials Group [ACTG] toxicity scale); Serum creatinine measuring > 1.5 x ULN; Total bilirubin > 2x ULN; Neutropenia (absolute neutrophil count < 1000/mm3); Presence of any clinically significant disease or findings during screening, that in the opinion of the investigator could compromise the safety of the subject; Patient is female and (willing to become) pregnant or breast-feeding; Any other condition which, in the opinion of the investigator, may interfere with the evaluation of the study objectives.